HUP0004396A3 - Pharmaceutical compositions containing hydroxylated cholesterol lowering agent as inhibitor of lipoprotein oxidation - Google Patents
Pharmaceutical compositions containing hydroxylated cholesterol lowering agent as inhibitor of lipoprotein oxidationInfo
- Publication number
- HUP0004396A3 HUP0004396A3 HU0004396A HUP0004396A HUP0004396A3 HU P0004396 A3 HUP0004396 A3 HU P0004396A3 HU 0004396 A HU0004396 A HU 0004396A HU P0004396 A HUP0004396 A HU P0004396A HU P0004396 A3 HUP0004396 A3 HU P0004396A3
- Authority
- HU
- Hungary
- Prior art keywords
- inhibitor
- pharmaceutical compositions
- compositions containing
- lowering agent
- cholesterol lowering
- Prior art date
Links
- 102000004895 Lipoproteins Human genes 0.000 title 1
- 108090001030 Lipoproteins Proteins 0.000 title 1
- 239000003529 anticholesteremic agent Substances 0.000 title 1
- 229940127226 anticholesterol agent Drugs 0.000 title 1
- 150000001841 cholesterols Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003647 oxidation Effects 0.000 title 1
- 238000007254 oxidation reaction Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6688897P | 1997-11-25 | 1997-11-25 | |
| PCT/US1998/023483 WO1999026583A2 (en) | 1997-11-25 | 1998-11-04 | Inhibtion of lipoprotein oxidation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0004396A2 HUP0004396A2 (hu) | 2001-06-28 |
| HUP0004396A3 true HUP0004396A3 (en) | 2003-04-28 |
Family
ID=22072341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0004396A HUP0004396A3 (en) | 1997-11-25 | 1998-11-04 | Pharmaceutical compositions containing hydroxylated cholesterol lowering agent as inhibitor of lipoprotein oxidation |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6362236B1 (hu) |
| EP (1) | EP1047421A2 (hu) |
| JP (1) | JP2001523694A (hu) |
| KR (3) | KR100539644B1 (hu) |
| CN (1) | CN1160068C (hu) |
| AR (1) | AR015487A1 (hu) |
| AU (1) | AU759376B2 (hu) |
| BR (1) | BR9815039A (hu) |
| CA (1) | CA2303864A1 (hu) |
| CO (1) | CO4970835A1 (hu) |
| HK (1) | HK1033095A1 (hu) |
| HU (1) | HUP0004396A3 (hu) |
| IL (1) | IL135154A (hu) |
| IS (1) | IS5413A (hu) |
| NO (1) | NO20002639L (hu) |
| NZ (1) | NZ503598A (hu) |
| PE (1) | PE134199A1 (hu) |
| PL (1) | PL341397A1 (hu) |
| TR (1) | TR200001522T2 (hu) |
| TW (1) | TW552137B (hu) |
| UY (1) | UY25268A1 (hu) |
| WO (1) | WO1999026583A2 (hu) |
| ZA (1) | ZA9810743B (hu) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030040505A1 (en) * | 2000-03-31 | 2003-02-27 | The Regents Of The University Of California | Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions |
| US7250304B2 (en) * | 2000-03-31 | 2007-07-31 | The Regents Of The University Of California | Functional assay of high-density lipoprotein |
| US20030114497A1 (en) * | 2001-07-31 | 2003-06-19 | Laman Alani | Pharmaceutical compositions of amlodipine and atorvastatin |
| HUE036646T2 (hu) | 2003-01-23 | 2018-07-30 | Esperion Therapeutics Inc | Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra |
| US20060194981A1 (en) * | 2005-02-26 | 2006-08-31 | Jass Paul A | Process for preparation of probucol derivatives |
| WO2006104399A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
| ES2862336T3 (es) | 2008-09-02 | 2021-10-07 | Amarin Pharmaceuticals Ie Ltd | Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma |
| CN102458109B (zh) | 2009-04-29 | 2015-02-11 | 阿马里纳制药公司 | 稳定的药物组合物和使用其的方法 |
| CN106822080A (zh) | 2009-04-29 | 2017-06-13 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| SG10201708950XA (en) | 2009-06-15 | 2017-12-28 | Ian Osterloh | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| AU2010298222B2 (en) * | 2009-09-23 | 2017-01-05 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| WO2012074930A2 (en) | 2010-11-29 | 2012-06-07 | Amarin Pharma, Inc. | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| JP2015522029A (ja) | 2012-06-29 | 2015-08-03 | アマリン ファーマシューティカルス アイルランド リミテッド | スタチン療法中の患者における心血管系イベントの危険性を減少させる方法 |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| KR101665180B1 (ko) | 2014-07-01 | 2016-10-14 | 순천향대학교 산학협력단 | 아포지단백질 a-i 돌연변이체 g59v를 포함하는 항산화성 펩타이드 및 이를 포함하는 항산화 조성물 |
| MX2017011499A (es) | 2015-03-13 | 2018-03-26 | Esperion Therapeutics Inc | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| CN112218630A (zh) | 2018-09-24 | 2021-01-12 | 阿马里纳药物爱尔兰有限公司 | 降低受试者的心血管事件的风险的方法 |
| BR112021025964A2 (pt) | 2019-06-21 | 2022-05-24 | Esperion Therapeutics Inc | Formas de sal de ácido bempedoico e métodos para uso das mesmas |
| WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
-
1998
- 1998-11-04 NZ NZ503598A patent/NZ503598A/en unknown
- 1998-11-04 KR KR10-2000-7005641A patent/KR100539644B1/ko not_active IP Right Cessation
- 1998-11-04 WO PCT/US1998/023483 patent/WO1999026583A2/en not_active Application Discontinuation
- 1998-11-04 HU HU0004396A patent/HUP0004396A3/hu unknown
- 1998-11-04 BR BR9815039-1A patent/BR9815039A/pt not_active Application Discontinuation
- 1998-11-04 KR KR1020057014824A patent/KR20050086975A/ko not_active Application Discontinuation
- 1998-11-04 US US09/485,250 patent/US6362236B1/en not_active Expired - Fee Related
- 1998-11-04 PL PL98341397A patent/PL341397A1/xx not_active Application Discontinuation
- 1998-11-04 AU AU15188/99A patent/AU759376B2/en not_active Ceased
- 1998-11-04 CA CA002303864A patent/CA2303864A1/en not_active Abandoned
- 1998-11-04 EP EP98959378A patent/EP1047421A2/en not_active Withdrawn
- 1998-11-04 CN CNB988112671A patent/CN1160068C/zh not_active Expired - Fee Related
- 1998-11-04 IL IL13515498A patent/IL135154A/xx not_active IP Right Cessation
- 1998-11-04 TR TR2000/01522T patent/TR200001522T2/xx unknown
- 1998-11-04 JP JP2000521788A patent/JP2001523694A/ja not_active Abandoned
- 1998-11-04 KR KR1020057021847A patent/KR100586754B1/ko not_active IP Right Cessation
- 1998-11-24 PE PE1998001143A patent/PE134199A1/es not_active Application Discontinuation
- 1998-11-24 UY UY25268A patent/UY25268A1/es not_active Application Discontinuation
- 1998-11-24 CO CO98069227A patent/CO4970835A1/es unknown
- 1998-11-24 ZA ZA9810743A patent/ZA9810743B/xx unknown
- 1998-11-24 AR ARP980105959A patent/AR015487A1/es unknown
- 1998-11-25 TW TW087119590A patent/TW552137B/zh not_active IP Right Cessation
-
2000
- 2000-03-24 IS IS5413A patent/IS5413A/is unknown
- 2000-05-23 NO NO20002639A patent/NO20002639L/no unknown
-
2001
- 2001-06-04 HK HK01103822A patent/HK1033095A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| UY25268A1 (es) | 1999-07-19 |
| AU759376B2 (en) | 2003-04-10 |
| NO20002639D0 (no) | 2000-05-23 |
| IS5413A (is) | 2000-03-24 |
| EP1047421A2 (en) | 2000-11-02 |
| AU1518899A (en) | 1999-06-15 |
| CN1279605A (zh) | 2001-01-10 |
| CA2303864A1 (en) | 1999-06-03 |
| TR200001522T2 (tr) | 2000-12-21 |
| KR100539644B1 (ko) | 2005-12-29 |
| KR20050113288A (ko) | 2005-12-01 |
| JP2001523694A (ja) | 2001-11-27 |
| CO4970835A1 (es) | 2000-11-07 |
| PE134199A1 (es) | 2000-01-20 |
| HUP0004396A2 (hu) | 2001-06-28 |
| KR20050086975A (ko) | 2005-08-30 |
| KR100586754B1 (ko) | 2006-06-08 |
| HK1033095A1 (en) | 2001-08-17 |
| WO1999026583A2 (en) | 1999-06-03 |
| IL135154A (en) | 2005-05-17 |
| NZ503598A (en) | 2002-06-28 |
| BR9815039A (pt) | 2001-03-20 |
| KR20010032401A (ko) | 2001-04-16 |
| PL341397A1 (en) | 2001-04-09 |
| IL135154A0 (en) | 2001-05-20 |
| US6362236B1 (en) | 2002-03-26 |
| ZA9810743B (en) | 1999-05-31 |
| TW552137B (en) | 2003-09-11 |
| WO1999026583A3 (en) | 1999-12-09 |
| CN1160068C (zh) | 2004-08-04 |
| NO20002639L (no) | 2000-05-23 |
| AR015487A1 (es) | 2001-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0004396A3 (en) | Pharmaceutical compositions containing hydroxylated cholesterol lowering agent as inhibitor of lipoprotein oxidation | |
| IL133420A0 (en) | Pharmaceutical composition for combination of piperidinoalkanol-decongestant | |
| NZ514350A (en) | Compositions and methods for effecting the levels of cholesterol | |
| HUP0001219A3 (en) | Pharmaceutical compositions containing compounds of neurotrophic effect | |
| IL132388A0 (en) | Kappa-opioid agonist compounds pharmaceutical compositions and method of prevention and treatment of pruritus therewith | |
| HUP0303040A3 (en) | Compositions and methods for lowering plasma lipoprotein and risk factors of cardiovascular diseases | |
| HUP0201479A2 (en) | Novel macrocyclic compounds as metalloprotease inhibitors and pharmaceutical compositions containing them | |
| HUP0105160A3 (en) | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-betha-cyclodextrin or 2-hydroxypropyl-betha-cyclodextrin and method for its preparation and pharmaceutical compositions containing them | |
| HU9603140D0 (en) | Pharmaceutical compositions catalyzing decomposition of peroxy-nitrite | |
| ZA986532B (en) | Benefit agent compositions comprising mixtures of alpha-hydroxy esters. | |
| AU3591301A (en) | Ester derivatives of dimethylpropionic acid and pharmacetuical compositions containing them | |
| ZA989997B (en) | Compositions of lipid lowering agents. | |
| AU2002218461A1 (en) | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | |
| IL156015A0 (en) | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | |
| GB9409944D0 (en) | New compositions of matter | |
| IL150865A0 (en) | Dual inhibitors of cholesterol ester and wax ester synthesis for sebaceous gland disorders | |
| EP1084108A4 (en) | SPLA 2 INHIBITORS FOR THE TREATMENT OF DISEASES | |
| IL129220A0 (en) | A pharmaceutical composition for lowering plasma levels of lipoprotein (a) | |
| GB9405234D0 (en) | New compositions of matter | |
| IL125316A0 (en) | Novel compositions for treatment of atherosclerosis and related conditions | |
| AU3192397A (en) | Cholesterol lowering pharmaceutical composition | |
| KR100248098B1 (en) | Pharmaceutical composition for the treatment of dementia | |
| GB9712029D0 (en) | New compositions of matter | |
| GB9715163D0 (en) | New compositions of matter | |
| IL124930A0 (en) | Natural compositions for the prevention of ldl oxidation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |